{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T08:20:02Z","timestamp":1793262002897,"version":"4.5.0"},"reference-count":55,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,3,6]],"date-time":"2023-03-06T00:00:00Z","timestamp":1678060800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002973","name":"Daiichi-Sankyo","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002973","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Progress in Cardiovascular Diseases"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1016\/j.pcad.2023.03.001","type":"journal-article","created":{"date-parts":[[2023,3,6]],"date-time":"2023-03-06T19:47:21Z","timestamp":1678132041000},"page":"2-11","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":70,"special_numbering":"C","title":["Bempedoic acid in the management of lipid disorders and cardiovascular risk. 2023 position paper of the International Lipid Expert Panel (ILEP)"],"prefix":"10.1016","volume":"79","author":[{"given":"Maciej","family":"Banach","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter E.","family":"Penson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Farnier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zlatko","family":"Fras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gustavs","family":"Latkovskis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich","family":"Laufs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Paneni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Parini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Pirro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u017deljko","family":"Reiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michal","family":"Vrablik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Escobar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"25","key":"10.1016\/j.pcad.2023.03.001_bb0005","doi-asserted-by":"crossref","first-page":"2982","DOI":"10.1016\/j.jacc.2020.11.010","article-title":"GBD-NHLBI-JACC Global burden of cardiovascular diseases writing group. Global burden of cardiovascular diseases and risk factors, 1990-2019: update from the GBD 2019 study","volume":"76","author":"Roth","year":"2020","journal-title":"J Am Coll Cardiol"},{"issue":"32","key":"10.1016\/j.pcad.2023.03.001_bb0010","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1093\/eurheartj\/ehx144","article-title":"Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European atherosclerosis society consensus panel","volume":"38","author":"Ference","year":"2017","journal-title":"Eur Heart J"},{"key":"10.1016\/j.pcad.2023.03.001_bb0015","doi-asserted-by":"crossref","first-page":"e15","DOI":"10.1016\/j.atherosclerosissup.2021.01.004","article-title":"The prevalence of cardiovascular risk factors and cardiovascular disease among primary care patients in Poland: results from the LIPIDOGRAM2015 study","volume":"42","author":"J\u00f3\u017awiak","year":"2020","journal-title":"Atheroscler Suppl"},{"issue":"1","key":"10.1016\/j.pcad.2023.03.001_bb0020","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1186\/s12916-020-01792-7","article-title":"LDL-C: lower is better for longer-even at low risk","volume":"18","author":"Penson","year":"2020","journal-title":"BMC Med"},{"issue":"10059","key":"10.1016\/j.pcad.2023.03.001_bb0025","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1016\/S0140-6736(16)31357-5","article-title":"Interpretation of the evidence for the efficacy and safety of statin therapy","volume":"388","author":"Collins","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.pcad.2023.03.001_bb0030","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s12916-016-0550-5","article-title":"Is statin-modified reduction in lipids the most important preventive therapy for cardiovascular disease? A pro\/con debate","volume":"14","author":"Hobbs","year":"2016","journal-title":"BMC Med"},{"issue":"11","key":"10.1016\/j.pcad.2023.03.001_bb0035","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1093\/eurjpc\/zwaa047","article-title":"EU-wide cross-sectional observational study of lipid-modifying therapy use in secondary and primary care: the DA VINCI study","volume":"28","author":"Ray","year":"2021","journal-title":"Eur J Prev Cardiol"},{"issue":"1","key":"10.1016\/j.pcad.2023.03.001_bb0040","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach","year":"2020","journal-title":"Eur Heart J"},{"issue":"34","key":"10.1016\/j.pcad.2023.03.001_bb0045","doi-asserted-by":"crossref","first-page":"3213","DOI":"10.1093\/eurheartj\/ehac015","article-title":"Prevalence of statin intolerance: a meta-analysis","volume":"43","author":"Bytyci","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.pcad.2023.03.001_bb0050","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.atherosclerosis.2021.01.009","article-title":"Lipid-lowering therapies: better together","volume":"320","author":"Banach","year":"2021","journal-title":"Atherosclerosis"},{"issue":"3","key":"10.1016\/j.pcad.2023.03.001_bb0055","doi-asserted-by":"crossref","first-page":"e26","DOI":"10.1093\/cvr\/cvy301","article-title":"What have we learned about lipids and cardiovascular risk from PCSK9 inhibitor outcome trials: ODYSSEY and FOURIER?","volume":"115","author":"Banach","year":"2019","journal-title":"Cardiovasc Res"},{"issue":"11","key":"10.1016\/j.pcad.2023.03.001_bb0060","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s11883-021-00968-7","article-title":"RNA silencing in the management of Dyslipidemias","volume":"23","author":"Henney","year":"2021","journal-title":"Curr Atheroscler Rep"},{"issue":"2","key":"10.1016\/j.pcad.2023.03.001_bb0065","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1080\/13543784.2017.1280458","article-title":"Evaluating bempedoic acid for the treatment of hyperlipidaemia","volume":"26","author":"Penson","year":"2017","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.pcad.2023.03.001_bb0070","doi-asserted-by":"crossref","first-page":"13457","DOI":"10.1038\/ncomms13457","article-title":"Liver-specific ATP-citrate lyase inhibition by bempedoic acid decreases LDL-C and attenuates atherosclerosis","volume":"7","author":"Pinkosky","year":"2016","journal-title":"Nat Commun"},{"issue":"13","key":"10.1016\/j.pcad.2023.03.001_bb0075","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1016\/j.jacc.2013.05.050","volume":"62","author":"Ballantyne","year":"2013","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"10.1016\/j.pcad.2023.03.001_bb0080","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.jacl.2015.03.003","article-title":"Use of ETC-1002 to treat hypercholesterolemia in patients with statin intolerance","volume":"9","author":"Thompson","year":"2015","journal-title":"J Clin Lipidol"},{"issue":"7","key":"10.1016\/j.pcad.2023.03.001_bb0085","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1003121","article-title":"Lipid, blood pressure meta-analysis collaboration G, the international lipid expert P. efficacy and safety of bempedoic acid for the treatment of hypercholesterolemia: a systematic review and meta-analysis","volume":"17","author":"Cicero","year":"2020","journal-title":"PLoS Med"},{"issue":"10","key":"10.1016\/j.pcad.2023.03.001_bb0090","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1001\/jamacardio.2020.2314","article-title":"Association of bempedoic acid administration with atherogenic lipid levels in phase 3 randomized clinical trials of patients with hypercholesterolemia","volume":"5","author":"Banach","year":"2020","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.pcad.2023.03.001_bb0095","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.athplu.2022.05.003","article-title":"Estimated cardiovascular benefits of bempedoic acid in patients with established cardiovascular disease","volume":"49","author":"Gunn","year":"2022","journal-title":"Atheroscler Plus"},{"issue":"2","key":"10.1016\/j.pcad.2023.03.001_bb0100","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2021-048893","article-title":"Clinical efficacy and safety outcomes of bempedoic acid for LDL-C lowering therapy in patients at high cardiovascular risk: a systematic review and meta-analysis","volume":"12","author":"Lin","year":"2022","journal-title":"BMJ Open"},{"key":"10.1016\/j.pcad.2023.03.001_bb0105","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.ahj.2020.10.060","article-title":"Rationale and design of the CLEAR-outcomes trial: evaluating the effect of bempedoic acid on cardiovascular events in patients with statin intolerance","volume":"235","author":"Nicholls","year":"2021","journal-title":"Am Heart J"},{"key":"10.1016\/j.pcad.2023.03.001_bb0110","series-title":"Esperion Announces CLEAR Cardiovascular Outcomes Trial of NEXLETOL\u00ae (bempedoic acid) Meets Primary Endpoint In","author":"Esperion Therapeutics Inc","year":"2022"},{"key":"10.1016\/j.pcad.2023.03.001_bb0115","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2215024","article-title":"Bempedoic acid and cardiovascular outcomes in statin-intolerant patients","author":"Nissen","year":"2023","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.pcad.2023.03.001_bb0120","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.jacl.2020.08.009","article-title":"Bempedoic acid safety analysis: pooled data from four phase 3 clinical trials","volume":"14","author":"Bays","year":"2020","journal-title":"J Clin Lipidol"},{"issue":"14","key":"10.1016\/j.pcad.2023.03.001_bb0130","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1016\/j.jacc.2022.07.006","article-title":"2022 ACC expert consensus decision pathway on the role of nonstatin therapies for LDL-cholesterol lowering in the Management of Atherosclerotic Cardiovascular Disease Risk: a report of the American College of Cardiology Solution set Oversight Committee","volume":"80","author":"Lloyd-Jones","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pcad.2023.03.001_bb0135","series-title":"Bempedoic acid with ezetimibe for treating primary hypercholesterolaemia or mixed dyslipidaemia","first-page":"TA694","author":"Excellence NIfHaC","year":"2022"},{"issue":"6","key":"10.1016\/j.pcad.2023.03.001_bb0140","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.5114\/aoms\/141941","article-title":"PoLA\/CFPiP\/PCS\/PSLD\/PSD\/PSH guidelines on diagnosis and therapy of lipid disorders in Poland 2021","volume":"17","author":"Banach","year":"2021","journal-title":"Arch Med Sci"},{"issue":"37","key":"10.1016\/j.pcad.2023.03.001_bb0145","doi-asserted-by":"crossref","first-page":"3817","DOI":"10.1093\/eurheartj\/ehab204","article-title":"The international lipid expert panel (ILEP)-the role of \u201coptimal\u201d collaboration in the effective diagnosis and treatment of lipid disorders","volume":"42","author":"Banach","year":"2021","journal-title":"Eur Heart J"},{"issue":"17","key":"10.1016\/j.pcad.2023.03.001_bb0150","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1080\/14656566.2018.1532501","article-title":"Embracing the polypill as a cardiovascular therapeutic: is this the best strategy?","volume":"19","author":"Franczyk","year":"2018","journal-title":"Expert Opin Pharmacother"},{"issue":"6","key":"10.1016\/j.pcad.2023.03.001_bb0155","first-page":"1429","article-title":"2022: the year in cardiovascular disease - the year of upfront lipid lowering combination therapy","volume":"18","author":"Banach","year":"2022","journal-title":"Arch Med Sci"},{"key":"10.1016\/j.pcad.2023.03.001_bb0160","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2021.105499","article-title":"Optimal use of lipid-lowering therapy after acute coronary syndromes: a position paper endorsed by the international lipid expert panel (ILEP)","volume":"166","author":"Banach","year":"2021","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.pcad.2023.03.001_bb0165","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.atherosclerosis.2020.12.023","article-title":"Combination of bempedoic acid, ezetimibe, and atorvastatin in patients with hypercholesterolemia: a randomized clinical trial","volume":"320","author":"Rubino","year":"2021","journal-title":"Atherosclerosis."},{"issue":"5","key":"10.1016\/j.pcad.2023.03.001_bb0170","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1093\/eurjpc\/zwaa145","article-title":"Cellular senescence, telomeres, and cardiovascular risk in familial hypercholesterolaemia","volume":"29","author":"Banach","year":"2022","journal-title":"Eur J Prev Cardiol"},{"issue":"19","key":"10.1016\/j.pcad.2023.03.001_bb0175","doi-asserted-by":"crossref","DOI":"10.3390\/jcm10194302","article-title":"Clinical features of familial hypercholesterolemia in children and adults in EAS-FHSC regional Center for Rare Diseases in Poland","volume":"10","author":"Lewek","year":"2021","journal-title":"J Clin Med"},{"issue":"1","key":"10.1016\/j.pcad.2023.03.001_bb0180","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1177\/2047487319870342","article-title":"Genetic testing in familial hypercholesterolaemia: what does it add?","volume":"27","author":"Banach","year":"2020","journal-title":"Eur J Prev Cardiol"},{"issue":"5","key":"10.1016\/j.pcad.2023.03.001_bb0185","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1093\/eurjpc\/zwac032","article-title":"Homozygous familial hypercholesterolaemia: shedding new light on a rare but deadly condition","volume":"29","author":"Banach","year":"2022","journal-title":"Eur J Prev Cardiol"},{"issue":"11","key":"10.1016\/j.pcad.2023.03.001_bb0190","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1056\/NEJMoa1803917","article-title":"Safety and efficacy of Bempedoic acid to reduce LDL cholesterol","volume":"380","author":"Ray","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pcad.2023.03.001_bb0195","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.amjcard.2022.03.020","article-title":"Long-term safety and efficacy of Bempedoic acid in patients with atherosclerotic cardiovascular disease and\/or heterozygous familial hypercholesterolemia (from the CLEAR Harmony open-label extension study)","volume":"174","author":"Ballantyne","year":"2022","journal-title":"Am J Cardiol"},{"issue":"3","key":"10.1016\/j.pcad.2023.03.001_bb0200","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1002\/jcsm.12960","article-title":"Step-by-step diagnosis and management of the nocebo\/drucebo effect in statin-associated muscle symptoms patients: a position paper from the international lipid expert panel (ILEP)","volume":"13","author":"Penson","year":"2022","journal-title":"J Cachexia Sarcopenia Muscle"},{"issue":"47","key":"10.1016\/j.pcad.2023.03.001_bb0205","doi-asserted-by":"crossref","first-page":"4787","DOI":"10.1093\/eurheartj\/ehab358","article-title":"Nocebo\/drucebo effect in statin-intolerant patients: an attempt at recommendations","volume":"42","author":"Penson","year":"2021","journal-title":"Eur Heart J"},{"issue":"3","key":"10.1016\/j.pcad.2023.03.001_bb0210","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.jacl.2022.03.001","article-title":"Efficacy and safety of bempedoic acid in patients not receiving statins in phase 3 clinical trials","volume":"16","author":"Laufs","year":"2022","journal-title":"J Clin Lipidol"},{"issue":"7","key":"10.1016\/j.pcad.2023.03.001_bb0215","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.118.011662","article-title":"Efficacy and safety of Bempedoic acid in patients with hypercholesterolemia and statin intolerance","volume":"8","author":"Laufs","year":"2019","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.pcad.2023.03.001_bb0220","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.atherosclerosis.2018.06.002","article-title":"Efficacy and safety of bempedoic acid added to ezetimibe in statin-intolerant patients with hypercholesterolemia: a randomized, placebo-controlled study","volume":"277","author":"Ballantyne","year":"2018","journal-title":"Atherosclerosis."},{"key":"10.1016\/j.pcad.2023.03.001_bb0225","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.atherosclerosis.2021.08.035","article-title":"Lipid-lowering therapy use in primary and secondary care in Central and Eastern Europe: DA VINCI observational study","volume":"334","author":"Vrablik","year":"2021","journal-title":"Atherosclerosis."},{"issue":"23","key":"10.1016\/j.pcad.2023.03.001_bb0230","doi-asserted-by":"crossref","first-page":"5656","DOI":"10.3390\/jcm10235656","article-title":"The differences in the prevalence of cardiovascular disease, its risk factors, and achievement of therapeutic goals among urban and rural primary care patients in Poland: results from the LIPIDOGRAM 2015 study","volume":"10","author":"Studzi\u0144ski","year":"2021","journal-title":"J Clin Med"},{"issue":"2","key":"10.1016\/j.pcad.2023.03.001_bb0235","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1056\/NEJM199901143400207","article-title":"Atherosclerosis--an inflammatory disease","volume":"340","author":"Ross","year":"1999","journal-title":"N Engl J Med"},{"issue":"40","key":"10.1016\/j.pcad.2023.03.001_bb0240","doi-asserted-by":"crossref","first-page":"3641","DOI":"10.1093\/eurheartj\/ehy533","article-title":"Associations between very low concentrations of low density lipoprotein cholesterol, high sensitivity C-reactive protein, and health outcomes in the reasons for geographical and racial differences in stroke (REGARDS) study","volume":"39","author":"Penson","year":"2018","journal-title":"Eur Heart J"},{"issue":"12","key":"10.1016\/j.pcad.2023.03.001_bb0245","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","article-title":"Antiinflammatory therapy with Canakinumab for atherosclerotic disease","volume":"377","author":"Ridker","year":"2017","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.pcad.2023.03.001_bb0250","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1111\/bcp.15041","article-title":"Lipid, blood pressure meta-analysis collaboration G, international lipid expert P. Efficacy and safety of colchicine in patients with coronary artery disease: a systematic review and meta-analysis of randomized controlled trials","volume":"88","author":"Bytyci","year":"2022","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.pcad.2023.03.001_bb0255","doi-asserted-by":"crossref","DOI":"10.1016\/j.atherosclerosis.2023.03.020","article-title":"Bempedoic acid lowers high-sensitivity C-reactive protein and low-density lipoprotein cholesterol: analysis of pooled data from four phase 3 clinical trials","author":"Stroes","year":"2023","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.pcad.2023.03.001_bb0260","doi-asserted-by":"crossref","first-page":"13457","DOI":"10.1038\/ncomms13457","article-title":"Liver-specific ATP-citrate lyase inhibition by bempedoic acid decreases LDL-C and attenuates atherosclerosis","volume":"7","author":"Pinkosky","year":"2016","journal-title":"Nat Commun"},{"issue":"4","key":"10.1016\/j.pcad.2023.03.001_bb0265","doi-asserted-by":"crossref","DOI":"10.1093\/ehjopen\/oeac039","article-title":"The role of inflammation and the possibilities of inflammation reduction to prevent cardiovascular events","volume":"2","author":"Maierean","year":"2022","journal-title":"Eur Heart J Open"},{"key":"10.1016\/j.pcad.2023.03.001_bb0270","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2020.108369","article-title":"Effect of bempedoic acid on new onset or worsening diabetes: a meta-analysis","volume":"168","author":"Masson","year":"2020","journal-title":"Diabetes Res Clin Pract"},{"issue":"5","key":"10.1016\/j.pcad.2023.03.001_bb0275","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1111\/dom.14645","article-title":"Bempedoic acid in patients with type 2 diabetes mellitus, prediabetes, and normoglycaemia: a post hoc analysis of efficacy and glycaemic control using pooled data from phase 3 clinical trials","volume":"24","author":"Leiter","year":"2022","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"10.1016\/j.pcad.2023.03.001_bb0280","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1186\/s12933-022-01684-5","article-title":"Personalized management of dyslipidemias in patients with diabetes-it is time for a new approach (2022)","volume":"21","author":"Banach","year":"2022","journal-title":"Cardiovasc Diabetol"}],"container-title":["Progress in Cardiovascular Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0033062023000269?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0033062023000269?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T00:22:37Z","timestamp":1758500557000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0033062023000269"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":55,"alternative-id":["S0033062023000269"],"URL":"https:\/\/doi.org\/10.1016\/j.pcad.2023.03.001","relation":{},"ISSN":["0033-0620"],"issn-type":[{"value":"0033-0620","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bempedoic acid in the management of lipid disorders and cardiovascular risk. 2023 position paper of the International Lipid Expert Panel (ILEP)","name":"articletitle","label":"Article Title"},{"value":"Progress in Cardiovascular Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pcad.2023.03.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}